• Molecular NameAdinazolam
  • SynonymAdinazolamum [INN-Latin]
  • Weight351.841
  • Drugbank_IDDB00546
  • ACS_NO37115-32-5
  • Show 3D model
  • LogP (experiment)4.05
  • LogP (predicted, AB/LogP v2.0)1.96
  • pkaN/A
  • LogD (pH=7, predicted)1.09
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-3.84
  • LogSw (predicted, AB/LogsW2.0)0.2
  • Sw (mg/ml) (predicted, ACD/Labs)0.02
  • No.of HBond Donors0
  • No.of HBond Acceptors5
  • No.of Rotatable Bonds3
  • TPSA45.79
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyIt possesses anxiolytic, anticonvulsant, sedative, and antidepressant properties.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability39.0
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic. The main metabolite is N-desmethyladinazolam. The other two metabolites are alpha-hydroxyalprazolam and estazolam.
  • Half life<3 h
  • ExcretionRenal
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySigns of overdose may include muscle weakness, ataxia, dysarthria and particularly in children paradoxical excitement. In more severe cases diminished reflexes, confusion, and coma may ensue.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A